• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Durezol (difluprednate)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Durezol (difluprednate)

  • Profile

Profile

Contact Information

Website: https://www.durezolhcp.com/

Currently Enrolling Trials

    Show More

    Durezol (difluprednate) - 2 Indications

    Scroll down for more information on each indication:

    • for the treatment of inflammation and pain associated with ocular surgery; approved June 2008
    • for the treatment of endogenous anterior uveitis; approved June of 2012

    General Information

    Durezol is a sterile, topical anti-inflammatory corticosteroid for ophthalmic use. Corticosteroids inhibit the inflammatory response to a variety of inciting agents that may delay or slow healing. They inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation.

    Durezol is specifically indicated for:

    •  the treatment of inflammation and pain associated with ocular surgery.
    • the treatment of endogenous anterior uveitis.

    Mechanism of Action

    Durezol is a sterile, topical anti-inflammatory corticosteroid for ophthalmic use. Corticosteroids inhibit the inflammatory response to a variety of inciting agents that may delay or slow healing. They inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotreines by inhibiting the release of their common precursor arachidonic acid.

    Side Effects

    Adverse events associated with the use of Durezol may include, but are not limited to, the following:

    • elevated intraocular pressure
    • visual acuity and field defects
    • posterior subcapsular cataract formation
    • posterior subcapsular cataract formation
    • secondary ocular infection from pathogens
    • perforation of the globe
    • corneal edema
    • ciliary and conjunctival hyperemia
    • eye pain
    • photophobia
    • posterior capsule opacification
    • anterior chamber flare
    • conjunctival edema
    • blepharitis
  • Indication 1 - inflammation and pain associated with ocular surgery

  • approved June 2008

  • Dosing/Administration
  • Instill one drop into the conjunctival sac of the affected eye 4 times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks of the postoperative period, followed by 2 times daily for a week and then a taper based on the response.

  • Clinical Results
  • FDA approval of Durezol was based on the results of two clinical trials. These randomized, double-masked, placebo-controlled studies enrolled 327 subjects with an anterior chamber cell grade of less than or equal to 2 (a cell count of 10 or higher) after cataract surgery. The subjects received one drop of Durezol or placebo, self instilled either 2 (BID) or 4 (QID) times per day for 14 days, beginning the day after surgery. The presence of complete clearing (a cell count of 0) was assessed 8 and 15 days post-surgery using a slit lamp binocular microscope. In the intent-to-treat analyses of both studies, a significant benefit was seen in the QID Durezol-treated group in ocular inflammation and reduction of pain when compared with placebo. The results are as follows: Day Eight Anterior Chamber cell clearing was seen in 22% of the Durezol QID arm compared to 7% in the placebo group and reduction of pain was reported in 58% of the Durezol arm and 27% of the placebo arm (p<0.01 for both endpoints). Day Fifteen Anterior Chamber cell clearing was seen in 41% of the Durezol QID arm compared to 11% of the placebo arm and reduction of pain was reported in 63% of the Durezol arm and 35% of the placebo arm (p<0.01 for both endpoints).

    Indication 2 - endogenous anterior uveitis

    approved June of 2012

    Dosing/Administration
    Instill one drop into the conjunctival sac of the affected eye 4 times daily for 14 days followed by tapering as clinically indicated.
    Clinical Trial Results

    Clinical efficacy was evaluated in two randomized, double masked active controlled trials in which patients who presented with endogenous anterior uveitis were treated with either Durezol 4 times daily or prednisolone acetate ophthalmic suspension 1%, 8 times daily for 14 days. Both studies demonstrated that Durezol was equally effective as prednisolone acetate ophthalmic suspension 1% in treating subjects with endogenous anterior uveitis.

    Approval Date: 2008-06-01
    Company Name: Novartis
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • Revamp-360x240.png

      Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

    • AskTheExpertsGreen-360x240.png

      Ask the Experts: Managing Investigational Products

    • SurveywBlueBackground-360x240.png

      Survey Outlines Site Challenges, Successes on Diversity

    • PatientCentricity-360x240.png

      Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing